Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study
Sponsor: The Second Affiliated Hospital of Fujian Medical University
Summary
This is a single-arm, phase II study of camrelizumab combined with SOX regimen in subjects with resectable locally advanced gastric cancer. The patients will receive camrelizumab ,S-1 and oxaliplatin given every 3 weeks for 3 cycles as neoadjuvant therapy. After the surgery, adjuvant therapy which includes camrelizumab and SOX regimen will begin.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
29
Start Date
2020-09-16
Completion Date
2026-12-30
Last Updated
2023-09-28
Healthy Volunteers
No
Conditions
Interventions
Camrelizumab
200mg, intravenously, d1
SOX
SOX (S-1: 40\~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle)
Surgery
Surgery
Locations (1)
The Second Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China